Christopher M Longshaw (Christopher Longshaw)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 11

Top Topics

Replacement Therapy

Biofilm Formation

Klebsiella Pneumoniae

Top Venues

Microbiology spectrum

Antibiotics (Basel, Switzerland)

Antimicrobial agents and chemotherapy

The Journal of antimicrobial chemotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Anne Santerre Henriksen, Fabio Arena, Marie Attwood, Rafael Canton, Sören Gatermann, Thierry Naas, Ian Morrissey, Christopher M Longshaw, null null
In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations. Microbiology spectrum (2024)
Anne Santerre Henriksen, Katy Jeannot, Antonio Oliver, John D Perry, Mathias W Pletz, Stefania Stefani, Ian Morrissey, Christopher M Longshaw, null null
In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations. Microbiology spectrum 12 (4) (2024)
Anne Santerre Henriksen, Fabio Arena, Marie Attwood, Rafael Canton, Sören Gatermann, Thierry Naas, Ian Morrissey, Christopher M Longshaw, null null
In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations. Microbiology spectrum (2024)
Anne Santerre Henriksen, Katy Jeannot, Antonio Oliver, John D Perry, Mathias W Pletz, Stefania Stefani, Ian Morrissey, Christopher M Longshaw, null null
In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations. Microbiology spectrum 12 (4) (2024)
Anne Santerre Henriksen, Katy Jeannot, Antonio Oliver, John D Perry, Mathias W Pletz, Stefania Stefani, Ian Morrissey, Christopher M Longshaw, null null
In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations. Microbiology spectrum 12 (4) (2024)
Anne Santerre Henriksen, Katy Jeannot, Antonio Oliver, John D Perry, Mathias W Pletz, Stefania Stefani, Ian Morrissey, Christopher M Longshaw, null null
In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations. Microbiology spectrum (2024)
Anne Santerre Henriksen, Fabio Arena, Marie Attwood, Rafael Canton, Sören Gatermann, Thierry Naas, Ian Morrissey, Christopher M Longshaw, null null
In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations. Microbiology spectrum (2024)
Christopher M Longshaw, Anne Santerre Henriksen, Dana Dressel, Michelle Malysa, Christian Silvestri, Miki Takemura, Yoshinori Yamano, Takamichi Baba, Christine M Slover
Heteroresistance to cefiderocol in carbapenem-resistant Acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis. Microbiology spectrum (2023)
Christopher M Longshaw, Echols Roger, Anne Santerre Henriksen, Takamichi Baba, Sean Nguyen, Yoshinori Yamano
Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials. Antimicrobial agents and chemotherapy 66 (10) (2022)
Saoussen Oueslati, Pierre Bogaerts, Laurent Dortet, Sandrine Bernabeu, Hend Ben Lakhal, Christopher M Longshaw, Youri Glupczynski, Thierry Naas
In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium. Antibiotics (Basel, Switzerland) 11 (10) (2022)
Christopher M Longshaw, Anne Santerre Henriksen, Christine Slover, Yoshinori Yamano, J Andreas Karas
Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance. The Journal of antimicrobial chemotherapy 77 (10) (2022)